Faron Presents BEXMAB Knowledge at ASH Annual Assembly By Investing.com
Faron Prescribed drugs Ltd.(“Faron” or “the Firm”)Faron presents complete evaluation of optimistic…
Syndax Presents Constructive Revuforj ® (revumenib) Information in Acute Leukemias from A number of Trials, Together with the SAVE Mixture and AUGMENT-101 Trials, at 66th ASH Annual Assembly
“ 82% ORR (27 of 33 pts) and 48% CR/CRh (16 of…
Blueprint Medicines’ Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting
-- ASH data reinforce survival benefits of front-line AYVAKIT ® (avapritinib) use…
Beam Therapeutics Announces New Data from the BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting
All seven patients treated with BEAM-101 achieved hemoglobin F (HbF) induction >…
